Phase 1 Sleep Disorders Trial, Recruiting NCT05497180 Sponsor: University of Alberta Condition: Sleep Disorders
Back to Sleep Disorders

Phase 1 Sleep Disorders Trial, Recruiting

NCT05497180
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with mild obstructive sleep apnea or with snoring that is not related to sleep apnea
  • People who are 18 years of age or older
  • People who are able to give their informed consent to receive treatment and take part in the study

Who may not be able to join:

  • People who have previously been identified as not responding to oral appliance therapy (a mouthguard-type device) for sleep apnea
  • People who are currently receiving other active treatments for sleep apnea
  • People who have had surgery in the past involving the airway or breathing during sleep
  • People who have a craniofacial condition (a disorder affecting the structure of the face or skull), a syndrome-related disorder, or a neuromuscular condition (a condition affecting the nerves and muscles)
  • People who have an acute (sudden or urgent) medical condition that requires immediate medical attention — the trial site will refer such individuals to an appropriate doctor, and enrollment may only be considered once health conditions are stable (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
23 July 2022
Est. completion
1 July 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Snoring volume

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov